In these analyses, we similarly saw that the only significant association was between GLP-1 receptor agonist use and a decreased hazard of multiple myeloma (HR 0.64, 95% CI 0.42–0.96, p = 0.032). This evidence concerns the gene GLP1R and plasma cell myeloma.